?Mavacamten | USP/EP-Certified Myosin Modulator | Bulk API for Hypertrophic Cardiomyopathy?
?Google Keywords?: Mavacamten bulk supplier, cardiac myosin inhibitor API, HCM treatment, USP-certified cardiovascular drug

?? ?Product Overview?

Mavacamten (CAS 1642288-47-8) is a selective small-molecule modulator of cardiac myosin, designed to treat hypertrophic cardiomyopathy (HCM) by reducing excessive myocardial contractility. It targets the β-cardiac myosin-S1 ATPase pathway to normalize sarcomere function, improving cardiac output and symptom management?12. Approved for clinical use, it is pivotal in both therapeutic and cardiovascular research applications?16.

?? ?Key Advantages?

• ?High Purity?: ≥99% HPLC purity compliant with ?USP/EP? standards?12.

• ?Bulk Customization?: Available in 1kg–25kg batches with batch-specific COA, MSDS, and stability data?24.

• ?Solubility?: White crystalline powder soluble in DMSO (≥20 mg/ml) for preclinical formulations?23.

?? ?Applications?

• ?Hypertrophic Cardiomyopathy?: First-line therapy for reducing ventricular hypertrophy and improving cardiac function?12.

• ?Cardiovascular Drug Development?: Key reference standard for HCM drug discovery?36.

• ?Research?: Mechanistic studies on sarcomere dynamics and myocardial contractility regulation?37.

?? ?Quality Compliance?

• Certified under ?USP/EP? guidelines with heavy metals <20ppm and residual solvents <10ppm?24.

• Stability tested for 24 months at -20°C in airtight, light-protected packaging?24.

?? ?Market Trends?

The global HCM treatment market is projected to grow at ?8.2% CAGR (2025-2030)?, driven by rising demand for precision therapies like Mavacamten. Its targeted mechanism positions it as a cornerstone in cardiovascular pharmacotherapy?13.